In patients with resistance (i.e., progressive disease) to systemic PD-L1 checkpoint inhibitor monotherapy, subsequent intralesional IL2 therapy was able to induce a CR in 33% of patients with a potent increase in CD4+ and CD8+ cells from the tumor microenvironment infiltrate [36]. The gene discussed is CD8A; the disease is neoplasm.